Pear Therapeutics doubles down on its digital therapeutic psychiatry portfolio with new asset acquisitions

January 18, 2022 | Case Study

Pear Therapeutics is a digital therapeutics (DTx) company with multiple psychiatric products in commercial use. It was the first company to have a U.S. FDA–approved DTx, reSET. Since then, it has had two other products approved by the FDA: reSET-O, and Somryst. All three products are commercially available and are used to treat substance abuse disorder, opioid use disorder, and insomnia, respectively. Along with this, Pear has many products in the proof-of-concept phase, for disorders like schizophrenia, alcohol abuse, and PTSD. Pear is also looking to enter the depression space, further broadening its reach across its DTx-based psychiatry portfolio.